SCHEMBL30767304

SCHEMBL30767304

C[C@@H]1CN(c2ccc(-c3nn(COCC[Si](C)(C)C)c4cnc(N5CCn6c(Br)cnc6C5)nc34)cn2)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.38
HDAC1 Q13547 2/20 0.37
FGFR2 P21802 7/20 0.37
FGFR1 P11362 6/20 0.37
FGFR3 P22607 6/20 0.37
ACVR1 Q04771 6/20 0.37
GPR119 Q8TDV5 2/20 0.36
BMPR1A P36894 2/20 0.32
TGFBR1 P36897 2/20 0.32
ACVRL1 P37023 2/20 0.32
HAMP P81172 2/20 0.32
RET P07949 3/20 0.31
PIK3R1 P27986 2/20 0.31
PIK3CA P42336 2/20 0.31
PGK1 P00558 1/20 0.30
WNT3A P56704 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21891832 1.00 MAP4K4 (0.38) MAP4K4HDAC1FGFR2FGFR1FGFR3
SCHEMBL21808321 0.92 ACVR1 (0.39) FGFR2FGFR1FGFR3ACVR1BMPR1A
SCHEMBL21808320 0.92 ACVR1 (0.39) FGFR2FGFR1FGFR3ACVR1BMPR1A
SCHEMBL21846697 0.86 FGFR2 (0.43) MAP4K4HDAC1FGFR2FGFR1FGFR3
SCHEMBL30767291 0.86 FGFR2 (0.43) MAP4K4HDAC1FGFR2FGFR1FGFR3
SCHEMBL30767299 0.85 MAP4K4 (0.44) MAP4K4HDAC1FGFR2FGFR1FGFR3
SCHEMBL21846805 0.85 MAP4K4 (0.44) MAP4K4HDAC1FGFR2FGFR1FGFR3
SCHEMBL30767295 0.82 HDAC1 (0.41) MAP4K4HDAC1FGFR2FGFR1FGFR3
SCHEMBL21808409 0.77 FGFR1 (0.35) MAP4K4HDAC1FGFR2FGFR1FGFR3
SCHEMBL21808414 0.77 FGFR1 (0.35) MAP4K4HDAC1FGFR2FGFR1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2025-10-14 US disclosed
EP-3856348-B1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS INCYTE CORP (US) 2024-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof ALK, FGFR1, FGFR2 MAP4K4 315/4885HDAC1 1732/4885FGFR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.